tiprankstipranks
Advertisement
Advertisement
Antag Therapeutics Brings New CEO as Lead Obesity Candidate Advances to Phase 2a
PremiumPrivate CompaniesAntag Therapeutics Brings New CEO as Lead Obesity Candidate Advances to Phase 2a
15d ago
Antag Therapeutics Showcases First-in-Human AT7687 Data Ahead of Phase 2 Obesity Trials
Premium
Private Companies
Antag Therapeutics Showcases First-in-Human AT7687 Data Ahead of Phase 2 Obesity Trials
1M ago
Antag Therapeutics to Present AT7687 Data at 2026 ADA Scientific Sessions
Premium
Private Companies
Antag Therapeutics to Present AT7687 Data at 2026 ADA Scientific Sessions
1M ago
Antag Therapeutics Highlights Progress on AT7687 Ahead of Scientific Presentation
PremiumPrivate CompaniesAntag Therapeutics Highlights Progress on AT7687 Ahead of Scientific Presentation
2M ago
Antag Therapeutics Highlights Obesity Program and AT7687 Opportunity
Premium
Private Companies
Antag Therapeutics Highlights Obesity Program and AT7687 Opportunity
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100